Aviva’s Axsome Therapeutics AXSM Stock Holding History

Aviva’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,363	Closed	-$1.15M	–	873
2021 Q1	$1.15M	Buy	+20,363	New	+$1.43M	0.01%	888

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Aviva's AXSM Position: Q2 2021 in Review

Aviva sold out of Axsome Therapeutics (AXSM) in Q2 2021, closing a stake of 20,363 shares — an estimated $1.15M sold.

Aviva first reported a position in AXSM in Q1 2021 and held it in 1 quarter. The position peaked at $1.15M in Q1 2021. 176 funds tracked by Wall St. Rank hold AXSM as of Q2 2021.

Aviva reported no remaining Axsome Therapeutics position as of Q2 2021 after selling out during the quarter.
Aviva sold 20,363 Axsome Therapeutics shares in Q2 2021, an estimated $1.15M.
Aviva first reported a position in Axsome Therapeutics in Q1 2021 and held it in 1 quarter.
Aviva's Axsome Therapeutics position peaked at $1.15M in Q1 2021.
176 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.